CJC-1295 + Ipamorelin: How This Peptide Blend Works

CJC-1295 + Ipamorelin: How This Peptide Blend Works
Reading Time: 8 mins

Science & Medicine Peptides Growth Hormone Research
Investigative Science Report Two Keys, One Lock: The Science Behind the CJC-1295 / Ipamorelin Growth Hormone Blend The CJC-1295 / ipamorelin blend is an attempt to replicate and amplify the body's natural growth hormone rhythm using two molecules that enter the pituitary through separate receptor doors. The science behind the combination is genuinely interesting. The human evidence behind it is thin.
2025 · Science Desk ·
A Necessary Clarification: The Naming Problem
Critical Distinction "CJC-1295" and "CJC-1295 without DAC" are not the same molecule. CJC-1295 with DAC has a half-life of ~5.8–8.1 days and is the compound studied in published clinical trials. CJC-1295 without DAC (Modified GRF(1-29)) has a half-life of ~30 minutes and has no published placebo-controlled human trial data — despite being one of the most frequently used wellness peptides in the world.
CJC-1295 with DAC
CJC-1295 without DAC
Half-life
~5.8–8.1 days
~30 minutes
Human trials
Yes — published Phase 1/2
None published
Used in blends
Rarely
Standard — mimics natural pulses
Mechanism
Albumin-binding via DAC
Same GHRH receptor, no albumin binding
Component 1: CJC-1295 (No DAC) — The GHRH Signal Growth hormone-releasing hormone (GHRH) is a 44-amino acid peptide produced by the hypothalamic arcuate nucleus that binds GHRH receptors on pituitary somatotrophs, activating adenylyl cyclase, elevating cAMP, and driving GH synthesis and pulsatile secretion. Native GHRH has a half-life of roughly 7 minutes, degraded primarily by DPP-4. CJC-1295 without DAC is a 29-amino acid analog of GHRH(1-29) with four protective substitutions that resist DPP-4 cleavage, extending half-life to approximately 30 minutes. The published human pharmacodynamics come from trials of the DAC version (Teichman SL et al., J Clin Endocrinol Metab, 2006): a single injection in healthy adults produced 2- to 10-fold GH increases for 6+ days and 1.5- to 3-fold IGF-1 increases lasting 9–11 days. Ionescu & Frohman (2006) confirmed GH pulsatility was preserved — critical because tonic versus pulsatile GH elevation produces different body composition and receptor effects.
Important Historical Note The Phase II clinical program for CJC-1295 DAC (for HIV-associated lipodystrophy) was discontinued in 2006 following the death of a trial participant in Argentina. The attending physician concluded the most likely cause was pre-existing asymptomatic coronary artery disease with plaque rupture, unrelated to the drug. No regulatory development program for CJC-1295 in any form has been pursued since.
Component 2: Ipamorelin — The Selective GHS Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) first characterized in 1998 by Raun and colleagues at Novo Nordisk (European Journal of Endocrinology) in a paper titled "Ipamorelin, the first selective growth hormone secretagogue." It binds and activates GHS-R1a (the ghrelin receptor) on pituitary somatotrophs, triggering rapid GH pulses through a pathway — involving protein kinase C and intracellular calcium mobilization — distinct from the GHRH receptor's cAMP pathway. Bowers et al. demonstrated that simultaneous stimulation of GHRH receptors and GHS-R1a produces a supra-additive GH response greater than either alone. This is the mechanistic foundation for combining CJC-1295 with ipamorelin.
What Made Ipamorelin Different Earlier GHRPs (GHRP-6, GHRP-2) elevated ACTH and cortisol alongside GH. Ipamorelin, even at doses 200-fold above its GH-releasing ED50, produced ACTH and cortisol responses indistinguishable from GHRH alone. FSH, LH, prolactin, and TSH were also unaffected. This clean selectivity profile reduces concerns about chronic stress hormone elevation. Human PK data (Gobburu et al., Pharmaceutical Research, 1999; 40 volunteers): ipamorelin induced biologically meaningful GH secretion with peak concentration within ~40 minutes.
The Synergy Principle: Why the Combination Works in Theory GH secretion is regulated by a push-pull dynamic: GHRH stimulates release, somatostatin (SRIF) inhibits it. Natural GH pulses occur when GHRH peaks and somatostatin falls — primarily during slow-wave sleep. CJC-1295 (no DAC) mimics the GHRH push — amplifying somatotroph priming and GH synthesis. Ipamorelin provides a second, independent stimulus through GHS-R1a, which operates via a different intracellular pathway and also modestly suppresses somatostatin tone. When both receptors are activated together, GH output is greater than additive.
The no-DAC form is preferred for this combination because its ~30-minute half-life produces a discrete pulse rather than chronically elevated GH — preserving the pulsatile pattern associated with favorable body composition effects.
The combined effect window is typically complete within 3–4 hours of injection, making bedtime administration — to amplify the physiological nocturnal GH surge — the standard approach. What the Evidence Does and Does Not Show
GH and IGF-1 Elevation in Humans Solid for CJC-1295 DAC specifically (Teichman et al., 2006). The no-DAC form has the same mechanism but no formal human PK/PD trial. Ipamorelin has one small human PK study. The combination has no published randomized controlled human trial.
Body Composition Animal studies show GH secretagogues including ipamorelin increase lean mass and reduce fat mass. A 2025 preprint noted significantly improved muscle performance in murine models — but these findings are limited to animal studies. No controlled human body composition trial for the combination has been published.
The Approved Comparator: Tesamorelin Tesamorelin (Egrifta), FDA-approved 2010 for HIV-associated lipodystrophy, works through the same GHRH receptor pathway as CJC-1295 with completed Phase 3 trials demonstrating visceral fat reduction and established safety. It is the benchmark against which CJC-1295 should be measured — same mechanism, more data, regulatory approval.
Regulatory Status and Open Risks
Regulatory Status CJC-1295 (both forms) and ipamorelin appear on the WADA 2025 Prohibited List under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) and on the FDA's 2023 Category 2 bulk drug substance list, barring compounding for human use in the US.
IGF-1 and cancer. Chronically elevated IGF-1 is associated with increased cancer risk (colorectal, prostate, breast) in epidemiological studies. Whether the modest, pulsatile IGF-1 increases from secretagogue protocols carry meaningful long-term cancer risk is unknown. No prospective long-term study of GH secretagogue use and cancer incidence in healthy adults has been conducted. The ratio of IGF-1 to IGFBP-3 is the clinically relevant monitoring target. Glucose and insulin resistance. GH is counter-regulatory — it reduces insulin sensitivity. Chronic modest GH elevation can impair glucose metabolism over time, particularly in pre-diabetic individuals. Ipamorelin's long-term effects on glucose regulation are uncharacterized in humans. Water retention and joint discomfort are consistent class-effect side effects of GH elevation, typically transient and dose-related. The Bottom Line The CJC-1295 (no DAC) / ipamorelin blend is pharmacologically coherent in a way that many peptide combinations are not. The two-receptor synergy principle is backed by genuine mechanistic data. The combination rationale — GHRH push + ghrelin-pathway trigger = amplified pulsatile GH — is scientifically sound and mechanistically distinct from either compound alone. The deficit is entirely in the clinical evidence. We have human PK data for CJC-1295 DAC (not the no-DAC form being used), animal and cell data for the synergy, ipamorelin selectivity data from animal models and one small human PK study, and no controlled human trial of the combination for any clinical endpoint. Long-term safety in humans — particularly regarding IGF-1 elevation, glucose regulation, and cancer risk — is uncharacterized. Tesamorelin shows that the mechanism works and is approvable. Whether CJC-1295 without DAC + ipamorelin produces equivalent, superior, or inferior outcomes — in humans, at the doses being used, over the timescales people are using them — remains genuinely unknown.
Sources
  1. Teichman SL et al. Prolonged stimulation of GH and IGF-I by CJC-1295. J Clin Endocrinol Metab, 2006;91(3):799–805. pubmed.ncbi.nlm.nih.gov/16352683
  2. Ionescu M & Frohman LA. GH pulsatility preserved with CJC-1295. J Clin Endocrinol Metab, 2006;91(12):4792–4797. pubmed.ncbi.nlm.nih.gov/17018654
  3. Raun K et al. Ipamorelin, the first selective GH secretagogue. Eur J Endocrinol, 1998;139(5):552–561. academic.oup.com/ejendo
  4. Gobburu JVS et al. PK-PD modeling of ipamorelin in humans. Pharmaceutical Research, 1999;16:1412–1416.
  5. Bowers CY. GH releasing peptides — structure and kinetics. J Pediatr Endocrinol Metab, 1999. PMID: 10372741.
  6. Jette L et al. CJC-1295 as a long-lasting GRF analog. Endocrinology, 2005;146(7):3052–3058.
  7. Alba M et al. CJC-1295 normalizes growth in GHRH knockout mouse. Am J Physiol Endocrinol Metab, 2006;291(6):E1290–4.
  8. Svensson J et al. Ipamorelin and GHRP-6 increase bone mineral content in rats. J Endocrinol, 1998;159(3):503–512.
  9. Ishida J et al. GH secretagogues: history, mechanism, clinical development. JCSM Rapid Communications, 2020. onlinelibrary.wiley.com/doi/full/10.1002/rco2.9
  10. Preprints.org. Safety and Efficacy of Approved and Unapproved Peptide Therapies. December 2025. preprints.org/manuscript/202512.1011
  11. Aidsmap. Lipodystrophy study halted after patient death. July 2006. aidsmap.com
  12. WADA Prohibited List 2025. Category S2. wada-ama.org/en/prohibited-list
  13. FDA. Category 2 bulk drug substances, 2023. fda.gov/drugs/human-drug-compounding/…
  14. Tesamorelin (Egrifta) FDA Approval, 2010. accessdata.fda.gov
  15. Clemmons DR. Long-Acting Forms of GHRH and GH. Hormone Research, 2007;68 Suppl 5:178–81.
  16. Chikani V & Ho KKY. Action of GH on skeletal muscle. J Mol Endocrinol, 2014;52(1):R107–123.
  17. Johannsson G et al. GH treatment of abdominally obese men. J Clin Endocrinol Metab, 1997;82:727–734.
  18. Kim KR et al. Low-dose GH with diet restriction in obese adults. Hormone Research, 1999;51(2):78–84.
Science & Medicine Desk  ·  All external links open in a new tab  ·  2025